A practical review tool
A concise, research-backed set of questions for people exploring an ibogaine treatment clinic, their families, and referring clinicians. It is built for verification, not ratings or endorsements.
Before a decision
Ibogaine can involve serious medical risk, especially cardiac risk. A clinic’s answers should be clear, documented, and appropriate to the person’s health history. Use this checklist alongside the broader safety context on the Plain Beacon ibogaine decision guide, not as a substitute for individualized medical or legal advice.
Regulatory status and clinic practices can differ by location. Comparing the treatment locations under consideration can help keep questions focused on what is verifiable in the relevant setting.
For background on the substance itself, the ibogaine overview describes its psychoactive history and use context. Evidence and risk should be discussed without treating a clinic’s marketing language as a clinical assessment.
Stop one
Screening is a process, not a single question. A legitimate conversation should address health history, medications, cardiac risk, and what happens when a person is not an appropriate candidate.
Ask whether an ECG and relevant laboratory testing are available before treatment, how results are reviewed, and what findings would pause or rule out treatment. Cardiac rhythm assessment matters because ibogaine has been associated with potentially dangerous rhythm changes.
Ask: “Which tests are performed, who reviews them, and what results change the plan?”Ask how the clinic identifies cardiac risk, including personal history, family history, medications, electrolyte concerns, and prior test results. The FDA’s discussion of QT prolongation illustrates why rhythm-related risks and medication review require careful attention.
Ask: “How do you assess QT-related risk and medication interactions before admission?”Ask who is responsible for medical decisions, how credentials can be verified, who is physically present during treatment, and who can respond if a person deteriorates. Titles alone are not enough; request a plain explanation of roles and coverage.
Ask: “Who is on site during dosing, and what is each person’s verified role?”Stop two
Ask to see or have the clinic explain its written emergency procedures. The answer should cover monitoring, escalation, transfer arrangements, and how staff respond to cardiac symptoms, seizures, severe distress, or other acute changes. A clinic should be able to explain its plan without minimizing uncertainty.
Informed consent should describe material risks, possible benefits, alternatives, contraindications, and the limits of what is known. The U.S. HHS overview of informed consent emphasizes that consent is a process for understanding, not merely a signature.
Ask whether adverse events are documented and how they are reviewed or reported. Independent comparison tools such as clinic-selection information may help identify questions, but they cannot verify a particular clinic’s real-time practices.
Stop three
Ask what happens after treatment: who follows up, when contact occurs, how new symptoms are handled, and whether there is a written plan for integration, medication coordination, mental health support, and substance-use recovery needs. A plan that ends at discharge leaves important questions unanswered.
Clarify how the clinic communicates with a person’s existing clinicians, when appropriate and consented to. The support options described by Plain Beacon can help organize questions before a clinic call, while a review of claimed therapy benefits should be kept separate from decisions about individual safety and suitability.
Ask directly about adverse-event reporting practices: what is recorded, who reviews patterns, and whether a person can receive copies of their own relevant records. Transparent answers are more useful than broad assurances of safety.
Plain-language glossary
Terms can sound settled while their practical meaning varies. Ask the clinic to define how it uses each term in writing and how that definition affects screening, monitoring, and follow-up.
A flood dose refers to an amount intended to produce a prolonged, intense psychoactive experience. The term does not establish safety. It makes careful screening, monitoring, and emergency preparedness especially important.
Integration is planned support and follow-up intended to help a person process the experience and address practical recovery needs afterward. Ask who provides it, how long it lasts, and what happens if additional support is needed.
A contraindication is a condition, medication, or circumstance that may make a treatment inappropriate or unsafe. Ask the clinic to explain its exclusion criteria and how it handles uncertainty or incomplete records.
Keep the record
Ask for written information on screening requirements, medication disclosure, testing, exclusions, consent, emergency procedures, supervision, discharge criteria, and follow-up. Comparing those materials with the clinic information available online can reveal where important details are absent or inconsistent.
Do not change prescribed medication based only on a clinic’s general guidance. Ask what information the clinic needs, how interaction concerns are assessed, and whether it will coordinate with the prescribing clinician when appropriate. Its approach should account for individual history rather than offer a one-size-fits-all answer.
No matter the location, the core questions about screening, credentials, emergency planning, consent, and follow-up remain relevant. Policy context can change, so material about Texas ibogaine policy discussions may be useful context, but it does not replace direct verification with the clinic.
Pause. A high-stakes decision deserves time and specific answers. It may help to review the plant context through information about ibogaine-producing plants, then return to the practical question: what can the clinic document about the care it proposes for this person?